CXCL10 and COVID-19: Additionally, the FDA-approved 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitor atorvastatin inhibits CXCL10 and may be useful in the treatment of COVID-19 (Grip and Janciauskiene, 2009).